))
Could GLP2 receptor agonists be a new frontier in weight management medication?
Manage episode 442609851 series 3546736
Το περιεχόμενο παρέχεται από το Dr. Sue Pedersen. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Dr. Sue Pedersen ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.
We are now very well acquainted with the efficacy of GLP1 receptor agonists (GLP1RAs) in weight management, like semaglutide (Wegovy/Ozempic) and liraglutide (Saxenda), and the dual GLP1/GIP agonist tirzepatide (Zepbound/Mounjaro). What is GLP2 (yes two), and could GLP2 receptor agonism be an untapped frontier in weight management medication?
Learn more: https://drsue.ca/2024/09/could-glp2-receptor-agonists-be-a-new-frontier-in-weight-management-medication/
Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.
50 επεισόδια
Μοίρασέ το
